Why Neuren Pharmaceuticals is Karst Peak and Milford Asset Management's top biotech pick
Neuren Pharmaceuticals’ share price has almost doubled in six months, but investors think it’s still undervalued as it approaches its first FDA approval.
Source: afr.com